{"id":27440,"date":"2024-10-15T10:28:15","date_gmt":"2024-10-15T08:28:15","guid":{"rendered":"https:\/\/ggba.swiss\/?p=27440"},"modified":"2024-10-15T10:28:17","modified_gmt":"2024-10-15T08:28:17","slug":"lymphatica-medtech-secures-eur-17-9-million-to-advance-lymphedema-treatment","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/en\/lymphatica-medtech-secures-eur-17-9-million-to-advance-lymphedema-treatment\/","title":{"rendered":"Lymphatica Medtech secures EUR 17.9 million to advance lymphedema treatment"},"content":{"rendered":"\n<p><a href=\"https:\/\/lymphaticamedtech.com\/\">Lymphatica Medtech<\/a>&#8216;s flagship device, LymphoDrain, is a breakthrough in the treatment of lymphedema. Implanted subcutaneously using a minimally invasive technique, it replaces the natural function of lymphatic vessels and actively drains lymphatic fluid to reduce swelling and provide relief to patients. The device aims to revolutionize lymphedema treatment options, which currently include limited and often ineffective therapies.<\/p>\n\n\n\n<p>The funding round was co-led by <a href=\"https:\/\/www.panakes.it\/\">Panak\u00e8s Partners<\/a>, <a href=\"https:\/\/www.techwald.com\/\">TechWald Next S.p.A.<\/a>, and <a href=\"https:\/\/www.cdpventurecapital.it\/cdp-venture-capital\/\">CDP Venture Capital<\/a>\u2019s Digital Transition Fund, with participation from <a href=\"https:\/\/www.occident.group\/\">OCCIDENT<\/a>, <a href=\"http:\/\/www.zkb.ch\/\">Z\u00fcrcher Kantonalbank<\/a>, and <a href=\"https:\/\/www.clubdeglinvestitori.it\/\">Club Degli Investitori<\/a>. Existing investors, including High-Tech Gr\u00fcnderfonds (<a href=\"https:\/\/www.htgf.de\/\">HTGF<\/a>), also joined the round.<\/p>\n\n\n\n<p>The investment will also support Lymphatica&#8217;s international expansion with a new subsidiary in Italy to manage research and development (R&amp;D), manufacturing and clinical operations. This move further strengthens the company&#8217;s ability to meet growing demand and scale its pioneering solutions.<\/p>\n\n\n\n<p>Lymphatica&#8217;s leadership team has been strengthened with the appointment of Dan Rose as Chairman of the Board. Rose brings extensive experience from previous roles at LimFlow, Direct Flow Medical and Medtronic. Other new board members include Alessio Beverina, Managing Partner at Panak\u00e8s, and Lukas Guenther, Chief Investment Officer at TechWald Next.<\/p>\n\n\n\n<p>Dr. Marco Pisano, CEO and co-founder of Lymphatica, expressed his excitement about the company\u2019s future: \u201cThis funding enables us to push forward with the clinical development of our technology, bringing us closer to delivering a transformative solution for patients with lymphedema.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Lymphatica Medtech, a Lausanne-based clinical-stage company specializing in innovative treatments for lymphedema, has raised EUR 17.9 million in a Series B funding round.<\/p>\n","protected":false},"author":6,"featured_media":27441,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[833],"tags":[894,890,963,883,902],"class_list":["post-27440","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-life-science","tag-financing","tag-healthcare","tag-medical-devices","tag-oncology","tag-personalized-medicine"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Lymphatica Medtech secures EUR 17.9 million | GGBa<\/title>\n<meta name=\"description\" content=\"Lymphatica Medtech, a clinical-stage company specializing in treatments for lymphedema, has raised EUR 17.9 million.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/en\/lymphatica-medtech-secures-eur-17-9-million-to-advance-lymphedema-treatment\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lymphatica Medtech secures EUR 17.9 million | GGBa\" \/>\n<meta property=\"og:description\" content=\"Lymphatica Medtech, a clinical-stage company specializing in treatments for lymphedema, has raised EUR 17.9 million.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/en\/lymphatica-medtech-secures-eur-17-9-million-to-advance-lymphedema-treatment\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2024-10-15T08:28:15+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-15T08:28:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2024\/10\/Lymphatica-Medtech-1180x811-1.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/en\/lymphatica-medtech-secures-eur-17-9-million-to-advance-lymphedema-treatment\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/en\/lymphatica-medtech-secures-eur-17-9-million-to-advance-lymphedema-treatment\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"Lymphatica Medtech secures EUR 17.9 million to advance lymphedema treatment\",\"datePublished\":\"2024-10-15T08:28:15+00:00\",\"dateModified\":\"2024-10-15T08:28:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/en\/lymphatica-medtech-secures-eur-17-9-million-to-advance-lymphedema-treatment\/\"},\"wordCount\":250,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/en\/lymphatica-medtech-secures-eur-17-9-million-to-advance-lymphedema-treatment\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/10\/Lymphatica-Medtech-1180x811-1.jpeg\",\"keywords\":[\"Financing\",\"Healthcare\",\"Medical Devices\",\"Oncology\",\"Personalized Medicine\"],\"articleSection\":[\"Life sciences\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/en\/lymphatica-medtech-secures-eur-17-9-million-to-advance-lymphedema-treatment\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/en\/lymphatica-medtech-secures-eur-17-9-million-to-advance-lymphedema-treatment\/\",\"url\":\"https:\/\/ggba.swiss\/en\/lymphatica-medtech-secures-eur-17-9-million-to-advance-lymphedema-treatment\/\",\"name\":\"Lymphatica Medtech secures EUR 17.9 million | GGBa\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/en\/lymphatica-medtech-secures-eur-17-9-million-to-advance-lymphedema-treatment\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/en\/lymphatica-medtech-secures-eur-17-9-million-to-advance-lymphedema-treatment\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/10\/Lymphatica-Medtech-1180x811-1.jpeg\",\"datePublished\":\"2024-10-15T08:28:15+00:00\",\"dateModified\":\"2024-10-15T08:28:17+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"Lymphatica Medtech, a clinical-stage company specializing in treatments for lymphedema, has raised EUR 17.9 million.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/en\/lymphatica-medtech-secures-eur-17-9-million-to-advance-lymphedema-treatment\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/en\/lymphatica-medtech-secures-eur-17-9-million-to-advance-lymphedema-treatment\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ggba.swiss\/en\/lymphatica-medtech-secures-eur-17-9-million-to-advance-lymphedema-treatment\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/10\/Lymphatica-Medtech-1180x811-1.jpeg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/10\/Lymphatica-Medtech-1180x811-1.jpeg\",\"width\":1180,\"height\":811,\"caption\":\"Lymphatica Medtech is a company committed to significantly improving the well-being of patients suffering from lymphatic diseases with innovative products that effectively replace lymphatic drainage function without impacting the patient\u2019s lifestyle. | \u00a9 Lymphatica Medtech\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/en\/lymphatica-medtech-secures-eur-17-9-million-to-advance-lymphedema-treatment\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lymphatica Medtech secures EUR 17.9 million to advance lymphedema treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/en\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Lymphatica Medtech secures EUR 17.9 million | GGBa","description":"Lymphatica Medtech, a clinical-stage company specializing in treatments for lymphedema, has raised EUR 17.9 million.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/en\/lymphatica-medtech-secures-eur-17-9-million-to-advance-lymphedema-treatment\/","og_locale":"en_US","og_type":"article","og_title":"Lymphatica Medtech secures EUR 17.9 million | GGBa","og_description":"Lymphatica Medtech, a clinical-stage company specializing in treatments for lymphedema, has raised EUR 17.9 million.","og_url":"https:\/\/ggba.swiss\/en\/lymphatica-medtech-secures-eur-17-9-million-to-advance-lymphedema-treatment\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2024-10-15T08:28:15+00:00","article_modified_time":"2024-10-15T08:28:17+00:00","og_image":[{"width":1180,"height":811,"url":"https:\/\/ggba.swiss\/app\/uploads\/2024\/10\/Lymphatica-Medtech-1180x811-1.jpeg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Pierre-Yves Oehrli","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/en\/lymphatica-medtech-secures-eur-17-9-million-to-advance-lymphedema-treatment\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/en\/lymphatica-medtech-secures-eur-17-9-million-to-advance-lymphedema-treatment\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"Lymphatica Medtech secures EUR 17.9 million to advance lymphedema treatment","datePublished":"2024-10-15T08:28:15+00:00","dateModified":"2024-10-15T08:28:17+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/en\/lymphatica-medtech-secures-eur-17-9-million-to-advance-lymphedema-treatment\/"},"wordCount":250,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/en\/lymphatica-medtech-secures-eur-17-9-million-to-advance-lymphedema-treatment\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/10\/Lymphatica-Medtech-1180x811-1.jpeg","keywords":["Financing","Healthcare","Medical Devices","Oncology","Personalized Medicine"],"articleSection":["Life sciences"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/en\/lymphatica-medtech-secures-eur-17-9-million-to-advance-lymphedema-treatment\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/en\/lymphatica-medtech-secures-eur-17-9-million-to-advance-lymphedema-treatment\/","url":"https:\/\/ggba.swiss\/en\/lymphatica-medtech-secures-eur-17-9-million-to-advance-lymphedema-treatment\/","name":"Lymphatica Medtech secures EUR 17.9 million | GGBa","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/en\/lymphatica-medtech-secures-eur-17-9-million-to-advance-lymphedema-treatment\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/en\/lymphatica-medtech-secures-eur-17-9-million-to-advance-lymphedema-treatment\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/10\/Lymphatica-Medtech-1180x811-1.jpeg","datePublished":"2024-10-15T08:28:15+00:00","dateModified":"2024-10-15T08:28:17+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"Lymphatica Medtech, a clinical-stage company specializing in treatments for lymphedema, has raised EUR 17.9 million.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/en\/lymphatica-medtech-secures-eur-17-9-million-to-advance-lymphedema-treatment\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/en\/lymphatica-medtech-secures-eur-17-9-million-to-advance-lymphedema-treatment\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ggba.swiss\/en\/lymphatica-medtech-secures-eur-17-9-million-to-advance-lymphedema-treatment\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2024\/10\/Lymphatica-Medtech-1180x811-1.jpeg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/10\/Lymphatica-Medtech-1180x811-1.jpeg","width":1180,"height":811,"caption":"Lymphatica Medtech is a company committed to significantly improving the well-being of patients suffering from lymphatic diseases with innovative products that effectively replace lymphatic drainage function without impacting the patient\u2019s lifestyle. | \u00a9 Lymphatica Medtech"},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/en\/lymphatica-medtech-secures-eur-17-9-million-to-advance-lymphedema-treatment\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/en\/"},{"@type":"ListItem","position":2,"name":"Lymphatica Medtech secures EUR 17.9 million to advance lymphedema treatment"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/en\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/27440","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/comments?post=27440"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/27440\/revisions"}],"predecessor-version":[{"id":27444,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/27440\/revisions\/27444"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media\/27441"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media?parent=27440"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/categories?post=27440"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/tags?post=27440"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}